Jantec Pharma

Jantec Pharma is a clinical-stage biopharmaceutical company headquartered in Denmark, dedicated to developing oral, gut-restricted therapies for metabolic diseases such as type 2 diabetes and obesity. The company's lead candidate, JNT-001, is a potent and selective inhibitor of the Sodium/glucose cotransporter 1 (SGLT1) that acts locally in the small intestine to reduce glucose absorption and stimulate the secretion of gut hormones like GLP-1. By restricting the drug's activity to the gastrointestinal tract, Jantec aims to minimize systemic side effects while achieving significant metabolic benefits. This approach represents a novel paradigm in treating chronic metabolic conditions through non-systemic pharmacology. The company is backed by prominent life science investors and is advancing its pipeline through early clinical development.